Allergy

In this iteration of the Month in Review series, a list of highlighted stories in the allergy and immunology space covered in the month of November is provided.

An overview and landing page for future installments from HCPLive's 8th annual This Year in Medicine Series.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.

In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.

In this analysis, the benefits of 2’-FL for mothers’ offspring with regard to allergies were highlighted by investigators.

A new analysis highlights the seasonal patterns of airborne fungal spores that can be found in the central region of England, with a calendar developed to this same end.

These data were explored to identify risk, recommendations, and guidelines related to vaccine-related allergic reactions such as anaphylaxis.

Post-hoc analysis of EoE KIDS trial shows dupilumab benefits for pediatric eosinophilic esophagitis, effective in patients with prior therapy limitations.

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.

The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Psychology referrals for children with food allergies surged 11-fold in the last decade, but many still face limited access to therapy services due to geographic barriers.

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Incorporating baked milk products into a regular diet may improve growth and quality of life in milk-allergic children.

This review compares the clinical and real-world outcomes of drugs such as mepolizumab versus drugs such as benralizumab for severe eosinophilic asthma.

A study found infants under 1 year with food allergies can safely consume small doses of allergens, which helps reduce allergic reactions later in life.

Data show age may be a significant effect on results from contact dermatitis patch tests.

Patients who underwent FESS required less medication and had fewer allergy and pulmonology visits than patients who did not have surgery.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.